Skip to main content

01.12.2014 | Brief communication | Ausgabe 1/2014 Open Access

Journal of Ovarian Research 1/2014

The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer

Journal of Ovarian Research > Ausgabe 1/2014
Masanori Kobayashi, Asako Chiba, Hiromi Izawa, Eri Yanagida, Masato Okamoto, Shigetaka Shimodaira, Yoshikazu Yonemitsu, Yuta Shibamoto, Noboru Suzuki, Masaki Nagaya, The DC-vaccine study group at the Japan Society of Innovative Cell Therapy (J-SICT)
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1757-2215-7-48) contains supplementary material, which is available to authorized users.
Masanori Kobayashi, Asako Chiba contributed equally to this work.

Competing interests

The authors have no financial or personal relationships with people or organizations that could inappropriately influence this work.

Authors’ contributions

MK, AC, and MN conceived and designed the study and collected, assembled, analyzed, and interpreted the data. EY provided study materials. HI, YS, SS, MO, YY, and NS analyzed and interpreted the data. MK and MN wrote the manuscript and approved the final manuscript. All authors read and approved the final manuscript.



Despite the increased rate of complete response to initial chemotherapy, most patients with advanced ovarian cancer relapse and succumb to progressive disease. Dendritic cell (DC)-based immunotherapy has been developed as a novel strategy for generating antitumor immunity as part of cancer treatments. The present study aimed to assess the feasibility and clinical effects of DC therapy for recurrent ovarian cancer (ROC).


This retrospective study included 56 ROC patients who initially received standard chemotherapy followed by DC-based immunotherapy targeting synthesized peptides at 2 institutions between March 2007 and August 2013. The adverse events (AEs) and clinical responses were examined.


No serious treatment-related AEs were observed. Seventy one percent of the enrolled patients developed an immunologic response. The median survival time (MST) from ROC diagnosis was 30.4 months, and that from the first vaccination was 14.5 months. Albumin levels of ≥4.0 g/dL and lactate dehydrogenase levels of <200 IU/L before vaccination were identified as significant independent factors by multivariate Cox proportional hazard analysis. The MST from the first vaccination in patients with albumin levels of ≥4.0 and <4.0 g/dL were 19.9 and 11.6 months, respectively. The corresponding disease control rates were 36% and 15%, respectively.


Our results demonstrated the feasibility and potential clinical effectiveness of DC-based immunotherapy for ROC patients. Additionally, a good nutritional status might be an important factor for further clinical effects.
Additional file 1: Table S1: Clinical response to the DC vaccine according to neutrophil-to-lymphocyte ratio. Table S2. Patient demographics, treatment characteristics, and immunological responses. (DOCX 42 KB)
Additional file 2: Comparison of the overall survival rates according to the neutrophil-to-lymphocyte ratio (<4 [solid line] and ≥4 [dotted line]).(TIFF 1 MB)
Authors’ original file for figure 1
Authors’ original file for figure 2
Authors’ original file for figure 3
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2014

Journal of Ovarian Research 1/2014 Zur Ausgabe


Neu im Fachgebiet Gynäkologie und Geburtshilfe

Meistgelesene Bücher aus dem Fachgebiet

2014 | Buch

Perikonzeptionelle Frauenheilkunde

Fertilitätserhalt, Prävention und Management von Schwangerschaftsrisiken

Ein Praxisbuch für alle, die in der Beratung und Betreuung von Schwangeren und Paaren mit Kinderwunsch tätig sind. Die Herausgeber und Autoren haben alle wichtigen Informationen zusammengetragen, um Frauen sicher zu beraten, zu betreuen und kompetent Verantwortung zu übernehmen.

Christian Gnoth, Peter Mallmann

2019 | Buch

Praxisbuch Gynäkologische Onkologie

Dieses kompakte und praxisrelevante Standardwerk richtet sich alle Ärzte in Klinik und Praxis, die Patientinnen mit bösartigen Tumoren des Genitales und der Mamma behandeln. Die 5. Auflage wurde komplett aktualisiert und auf der Basis …

Prof. Dr. Edgar Petru, Dr. Daniel Fink, Prof. Dr. Ossi R. Köchli, Prof. Dr. Sibylle Loibl

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Gynäkologie und bleiben Sie gut informiert – ganz bequem per eMail.